To understand the mechanism underlying the ROSA-mediated anti-inflammatory effects, we adopted network pharmacology approach and analyzed three databases of ROSA effects, gain-of-function TRPV3 mutations-associated OS and TRPV3-associated AD, and identified eight key targets, such as TNF, TGFB1, PTGS2, and MMP9, involved in ROSA-mediated alleviation of skin inflammation via inhibition of TRPV3 (Fig. 7A). The gene discussed is TGFB1; the disease is dermatitis.